On June 30, 2023, INOVIO PHARMACEUTICALS ($NASDAQ:INO) reported their second quarter FY2023 earnings results, showing total revenue of USD 0.2 million, representing a 70.5% decrease from the same quarter of the prior year. Net income for the quarter was USD -35.5 million, a decline of -108.5 million from the prior year’s corresponding quarter.
The stock opened at $0.4 and closed at the same price, down 4.5% from last closing price of $0.4. These results highlight the company’s strong financial performance in the second quarter of the fiscal year. This was mainly due to higher research and development costs, as well as costs related to expanding its marketing activities.
Overall, the strong financial performance of INOVIO PHARMACEUTICALS in the second quarter of FY2023 shows that the company is in good financial health and is well-poised to continue its growth in the future. Investors should watch for any further developments related to INOVIO PHARMACEUTICALS as the company looks to expand its product portfolio and continue to generate strong revenues. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Inovio Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inovio Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inovio Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Inovio Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
After analyzing INOVIO PHARMACEUTICALS‘s fundamentals, GoodWhale has concluded that it is classified as a ‘cheetah’ type of company. This means that it has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are looking for higher returns and are willing to take on more risk may find this company attractive. When looking at INOVIO PHARMACEUTICALS’s Star Chart, GoodWhale has found that it is strong in asset, medium in growth and weak in dividend, profitability. Additionally, its health score of 3/10 indicates that it is less likely to pay off debt and fund future operations. This means that investors should be aware of the risks associated with investing in this company. However, those with a higher risk tolerance may find value in investing in INOVIO PHARMACEUTICALS. More…
Risk Rating Analysis
Star Chart Analysis
The biotech industry is intensely competitive, with companies vying for market share in the race to develop new and innovative treatments. Inovio Pharmaceuticals Inc is no exception, and its competitors include Altimmune Inc, AgeX Therapeutics Inc, and Jounce Therapeutics Inc. All four companies are working to develop cutting-edge therapies that will improve patient outcomes and drive shareholder value.
Altimmune is a clinical-stage biopharmaceutical company that focuses on the development of immunotherapies for the treatment of chronic viral diseases, cancer, and autoimmune disorders. The company’s most advanced product candidates are T-cell therapies for the treatment of hepatitis B and HPV-related diseases. Altimmune has a market cap of $571.14M and a ROE of -31.9%. The company’s products are in various stages of development, with the most advanced in clinical trials.
– AgeX Therapeutics Inc ($NYSEAM:AGE)
AgeX Therapeutics Inc is a company that focuses on developing therapeutics related to the aging process. As of 2022, the company has a market cap of 25.8 million and a return on equity of 37.48%. The company’s focus on developing treatments for age-related conditions could prove to be a valuable endeavor as the population continues to age.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel cancer immunotherapies. Its products include JTX-2011, JTX-4014, and JTX-2056. The company was founded by Richard A. Barth, Ramy I. Ibrahim, and Robert Langer on December 12, 2013 and is headquartered in Cambridge, MA.
INOVIO Pharmaceuticals reported their second quarter FY2023 earnings results on June 30 2023, with total revenue of USD 0.2 million, indicating a decrease of 70.5% year-over-year. Net income for the quarter was USD -35.5 million, a decrease of -108.5 million from the same period in the prior year. This resulted in stock price dropping on the same day.
Investors will need to carefully consider the profitability and future prospects of INOVIO Pharmaceuticals when making investing decisions, as these figures suggest a significant decrease in performance. Fundamental analysis and research is necessary to make an informed investing decision on INOVIO Pharmaceuticals.